Quotas - 1998
[Federal Register Volume 63, Number 137 (Friday, July 17, 1998)]
[Notices]
[Pages 38671-38674]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 98-19084]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[DEA#167R]
Controlled Substances: Proposed Revised Aggregate Production
Quotas for 1998
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed revised 1998 aggregate production quotas.
SUMMARY: This notice proposes revised 1998 aggregate production quotas
for controlled substances in Schedules I and II of the Controlled
Substances Act (CSA).
DATES: Comments or objections should be received on or before August
17, 1998.
ADDRESSES: Send comments or objections to the Acting Deputy
Administrator, Drug Enforcement Administration, Washington, DC 20537,
Attn.: DEA Federal Register Representative (CCR).
FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug
Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-
7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires that the Attorney General establish aggregate production
quotas for each basic class of controlled substance listed in Schedules
I and II. This responsibility has been delegated to the Administrator
of the DEA by Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator of the DEA pursuant to Section 0.104 of
Title 28 of the Code of Federal Regulations.
On November 21, 1997, a notice of established initial 1998
aggregate production quotas for certain controlled substances in
Schedules I and II was published in the Federal Register (62 FR 62349).
The notice proposing initial
[[Page 38672]]
1998 aggregate production quotas (62 FR 46373) stipulated that the
Deputy Administrator of the DEA would adjust the quotas in early 1998
as provided for in Section 1303 of Title 21 of the Code of Federal
Regulations.
The proposed revised 1998 aggregate production quotas represent
those quantities of controlled substances that may be produced in the
United States in 1998 to provide adequate supplies of each substance
for: the estimated medical, scientific, research, and industrial needs
of the United States; lawful export requirements; and the establishment
and maintenance of reserve stocks. These quotas do not include imports
of controlled substances for use in industrial processes.
The proposed revisions are based on a review of 1997 year-end
inventories, 1997 disposition data submitted by quota applicants,
estimates of the medical needs of the United States, and other
information available to the DEA.
Therefore, under the authority vested in the Attorney General by
Section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the
Administrator of the DEA by Section 0.100 of Title 28 of the Code of
Federal Regulations, and redelegated to the Deputy Administrator
pursuant to Section 0.104 of Title 28 of the Code of Federal
Regulations, the Acting Deputy Administrator hereby proposes the
following revised 1998 aggregate production quotas for the following
controlled substances, expressed in grams of anhydrous acid or base:
| Basic class |
Previously established
initial
1998 quotas |
Proposed revised
1998
quotas |
| SCHEDULE I |
| 2, 5-Dimethoxyamphetamine |
15,000,100 |
20,000,100 |
| 2, 5-Dimethoxy-4-ethylamphetamine (DOET) |
2 |
2 |
| 3-Methylfentanyl |
14 |
14 |
| 3-Methylthiofentanyl |
2 |
2 |
| 3,4-Methylenedioxyamphetamine (MDA) |
25 |
25 |
| 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) |
30 |
30 |
| 3,4-Methylenedioxymethamphetamine (MDMA) |
20 |
20 |
| 3,4,5-Trimethoxyamphetamine |
2 |
2 |
| 4-Bromo-2,5-Dimethoxyamphetamine (DOB) |
2 |
2 |
| 4-Bromo-2,5-Dimethoxyphenethylamine (2-CB) |
2 |
2 |
| 4-Methoxyamphetamine |
100,100 |
100,100 |
| 4-Methylaminorex |
2 |
2 |
| 4-Methyl-2,5-Dimethoxyamphetamine (DOM) |
2 |
2 |
| 5-Methoxy-3,4-Methylenedioxyamphetamine |
2 |
2 |
| Acetyl-alpha-methylfentanyl |
2 |
2 |
| Acetylmethadol |
7 |
7 |
| Allylprodine |
2 |
2 |
| Alpha-acetylmethadol |
7 |
7 |
| Alpha-ethyltryptamine |
2 |
2 |
| Alphameprodine |
2 |
2 |
| Alpha-methadol |
2 |
2 |
| Alpha-methylfentanyl |
2 |
2 |
| Alphaprodine |
2 |
2 |
| Alpha-methylthiofentanyl |
2 |
2 |
| Aminorex |
7 |
7 |
| Beta-acetylmethadol |
2 |
2 |
| Beta-hydroxyfentanyl |
2 |
2 |
| Beta-hydroxy-3-methylfentanyl |
2 |
2 |
| Beta-methadol |
2 |
2 |
| Betaprodine |
2 |
2 |
| Bufotenine |
2 |
2 |
| Cathinone |
9 |
9 |
| Codeine-N-oxide |
2 |
2 |
| Diethyltryptamine |
2 |
2 |
| Difenoxin |
16,000 |
16,000 |
| Dihydromorphine |
7 |
7 |
| Dimethyltryptamine |
2 |
2 |
| Ethylamine Analog of PCP |
5 |
5 |
| Heroin |
2 |
2 |
| Hydroxypethidine |
2 |
2 |
| Lysergic acid diethylamide (LSD) |
57 |
57 |
| Mescaline |
7 |
7 |
| Methaqualone |
17 |
17 |
| Methcathione |
11 |
11 |
| Morphine-N-oxide |
2 |
2 |
| N-Ethylamphetamine |
7 |
7 |
| N-Hydroxy-3,4-Methylenedioxyamphetamine |
4 |
4 |
| N,N-Dimethylamphetamine |
7 |
7 |
| Noracymethadol |
2 |
2 |
| Norlevorphanol |
2 |
2 |
| Normethadone |
7 |
7 |
| Normorphine |
7 |
7 |
| Para-fluorofentanyl |
2 |
2 |
| Pholcodine |
2 |
2 |
| Psilocin |
2 |
2 |
| Psilocybin |
2 |
2 |
| Tetrahydrocannabinols |
26,000 |
31,000 |
| Thiofentanyl |
2 |
2 |
| Trimeperidine |
2 |
2 |
|
SCHEDULE II |
| 1-Phenylcyclohexylamine |
15 |
15 |
| 1-Piperidinocyclohexanecarbonitrile (PCC) |
12 |
12 |
| Alfentanil |
8,100 |
8,100 |
| Amobarbital |
12 |
12 |
| Amphetamine |
4,037,000 |
4,178,000 |
| Cocaine |
550,100 |
550,100 |
| Codeine (for sale) |
62,020,000 |
62,020,000 |
| Codeine (for conversion) |
18,460,000 |
23,906,000 |
| Desoxyephedrine 1,151,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription product and 32,000 grams for methamphetamine |
1,332,000 |
1,183,000 |
| Dextropropoxyphene |
109,500,000 |
109,500,000 |
| Dihydrocodeine |
189,000 |
46,000 |
| Diphenoxylate |
1,600,000 |
1,600,000 |
| Ecgonine |
651,000 |
651,000 |
| Ethylmorphine |
12 |
12 |
| Fentanyl |
202,000 |
202,000 |
| Glutethimide |
2 |
2 |
| Hydrocodone (for sale) |
13,908,000 |
16,314,000 |
| Hydrocodone (for conversion) |
3,000,000 |
3,000,000 |
| Hydromorphone |
766,000 |
766,000 |
| Isomethadone |
12 |
12 |
| Levo-alpha-acetylmethadol (LAAM) |
356,000 |
356,000 |
| Levomethorphan |
2 |
2 |
| Levorphanol |
15,000 |
15,000 |
| Meperidine |
9,311,000 |
9,745,000 |
| Methadone (for sale) |
3,790,000 |
5,413,000 |
| Methadone (for conversion) |
1,169,000 |
585,000 |
| Methadone Intermediate |
6,777,000 |
7,488,000 |
| Methamphetamine (for conversion) |
723,000 |
723,000 |
| Methylphenidate |
14,442,000 |
14,442,000 |
| Morphine (for sale) |
11,535,000 |
12,034,000 |
| Morphine (for conversion) |
75,918,000 |
75,918,000 |
| Nabilone |
2 |
2 |
| Noroxymorphone (for sale) |
25,000 |
25,000 |
| Noroxymorphone (for conversion) |
2,117,000 |
2,177,000 |
| Opium |
615,000 |
615,000 |
| Oxycodone (for sale) |
9,032,000 |
9,451,000 |
| Oxymorphone |
120,000 |
126,000 |
| Pentobarbital |
16,562,000 |
16,562,000 |
| Phencyclidine |
60 |
60 |
| Phenmetrazine |
2 |
2 |
| Phenylacetone |
10 |
10 |
| Secobarbital |
301,000 |
397,000 |
| Sufentanil |
700 |
1,800 |
| Thebaine |
9,580,000 |
13,230,000 |
The Acting Deputy Administrator further proposes that aggregate
production quotas for all other Schedules I and II controlled
substances including Secs. 1308.11 and 1308.12 of Title 21 of the Code
of Federal Regulations remain at zero.
All interested persons are invited to submit their comments and
objections in writing regarding this proposal. A person may object to
or comment on the proposal relating to any of the above-mentioned
substances without filing comments or objections regarding the others.
If a person believes that one or more of these issues warrant a
hearing, the individual should so state and summarize the reasons for
this belief.
In the event that comments or objections to this proposal raise one
or more issues which the Acting Deputy Administrator finds warrant a
hearing, the Acting Deputy Administrator shall order a public hearing
by notice in the Federal Register, summarizing the issues to be heard
and setting the time for the hearing.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866. This action has been analyzed in accordance with
the principles and criteria contained in Executive Order 12612, and it
has been determined that this matter does not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.
The Acting Deputy Administrator hereby certifies that this action
will have no significant impact upon small entities whose interests
must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601
et seq. The establishment of aggregate production quotas for Schedule I
and II controlled substances is mandated by law and by international
treaty obligations. Aggregate production quotas apply to
[[Page 38674]]
approximately 200 DEA registered bulk and dosage from manufacturers of
Schedules I and II controlled substances. The quotas are necessary to
provide for the estimated medical, scientific, research and industrial
needs of the United States, for export requirements and the
establishment and maintenance of reserve stocks. While aggregate
production quotas are of primary importance to large manufacturers,
their impact upon small entities is neither negative nor beneficial.
Accordingly, the Acting Deputy Administrator has determined that this
action does not require a regulatory flexibility analysis.
Donnie R. Marshall,
Acting Deputy Administrator.
[FR Doc. 98-19084 Filed 7-16-98; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
